Compare IMRX & SPXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMRX | SPXX |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.3M | 314.9M |
| IPO Year | 2021 | 2005 |
| Metric | IMRX | SPXX |
|---|---|---|
| Price | $4.96 | $15.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $17.20 | N/A |
| AVG Volume (30 Days) | ★ 812.2K | 54.6K |
| Earning Date | 03-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.10 | $14.33 |
| 52 Week High | $10.08 | $18.35 |
| Indicator | IMRX | SPXX |
|---|---|---|
| Relative Strength Index (RSI) | 45.29 | 25.51 |
| Support Level | $4.83 | N/A |
| Resistance Level | $5.36 | $18.18 |
| Average True Range (ATR) | 0.29 | 0.24 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 23.51 | 0.00 |
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on approximately 35%-75% of the notional value of the Fund's equity portfolio in an effort to enhance the Fund's risk-adjusted returns.